



November 7, 2017

## **Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting**

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- [Five Prime Therapeutics, Inc.](#) (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, previously announced that the abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, [cabiralizumab \(FPA008\)](#), with Opdivo® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, has been selected for a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland.

Five Prime will host a conference call and live audio webcast on Saturday, November 11, 2017, at 5:45 p.m. (ET). Lewis T. "Rusty" Williams, President and Chief Executive Officer, Aron Knickerbocker, Chief Operating Officer, Helen Collins, Chief Medical Officer and Dr. Zev Wainberg, Assistant Professor of Medicine at UCLA, will review the data presented at SITC earlier that day.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at [www.fiveprime.com](http://www.fiveprime.com). Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 4092848.

The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

### **About Five Prime**

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit [www.fiveprime.com](http://www.fiveprime.com).

### **CONTACT:**

Derek Cole  
Investor Relations Advisory Solutions  
720-785-4497  
[derek.cole@iradvisory.com](mailto:derek.cole@iradvisory.com)

Source: Five Prime Therapeutics, Inc.

News Provided by Acquire Media